Document is current
Any future updates will be listed below
-
Authors
Vickovic, S. https://orcid.org/0000-0003-0985-9885
Lötstedt, B. https://orcid.org/0000-0003-3545-5489
Klughammer, J. https://orcid.org/0000-0002-3628-9278
Mages, S.
Segerstolpe, Å
Rozenblatt-Rosen, O. https://orcid.org/0000-0001-6313-3570
Regev, A. https://orcid.org/0000-0003-3293-3158
-
Funding
Funding for this research was provided by:
Knut och Alice Wallenbergs Stiftelse
Svenska Sällskapet för Medicinsk Forskning
Royal Swedish Academy of Sciences
Human Frontier Science Program (LT000452/2019-L)
Deutsche Forschungsgemeinschaft (MA 9108/1-1)
Howard Hughes Medical Institute
Klarman Family Foundation
- License Information
-
More Information
Article History
Received: 21 October 2020
Accepted: 24 January 2022
First Online: 10 February 2022
Competing interests
: A.R. is a founder and equity holder of Celsius Therapeutics, an equity holder in Immunitas Therapeutics and until August 31, 2020 was a SAB member of Syros Pharmaceuticals, Neogene Therapeutics, Asimov and ThermoFisher Scientific. From August 1, 2020, A.R. is an employee of Genentech. O.R.R. is a co-inventor on patent applications filed by the Broad Institute for inventions related to single cell genomics. She has given numerous lectures on the subject of single cell genomics to a wide variety of audiences and in some cases, has received remuneration to cover time and costs. O.R.R. is an employee of Genentech since October 19, 2020. S.V is an author on patents applied for by Spatial Transcriptomics AB (10X Genomics Inc). S.V. and A.R. are co-inventors on PCT/US2020/015481 relating to this work. The remaining authors declare no competing interests.
